cael-101: a monoclonal antibody therapy for al amyloidosis
Published 3 years ago • 1K plays • Length 2:31Download video MP4
Download video MP3
Similar videos
-
4:05
al amyloidosis special session highlights: therapeutic advances and ongoing trials in the field
-
5:14
current status & updates in the management of al amyloidosis
-
1:30
ongoing trials on antibody treatments for al amyloidosis
-
3:01
novel promising agents and clinical trials in amyloidosis
-
5:51
safety of hbi0101 (nxc-201), a novel academic anti-bcma car-t, in r/r al amyloidosis
-
15:10
update on cael-101 from caelum biosciences
-
1:35
vital results for birtamimab in al amyloidosis
-
2:32
ongoing trials in amyloidosis
-
10:31
cael-101 update
-
1:55
quantifying biomarkers on lambda amyloidogenic light chains to diagnose al amyloidosis
-
5:39
new organ response criteria in amyloidosis diagnosis
-
1:21
trends in allosct for good-risk aml: a longitudinal study
-
1:51
diagnosis and potential therapeutic options for aa amyloidosis
-
1:09
menin inhibitors for the treatment of aml: insights into the covalent-101 trial
-
1:29
the impact of clonal features on the survival of patients with non-cardiac al amyloidosis
-
0:56
cnty-101 in follicular lymphoma: a case study from the elipse-1 trial
-
1:59
the importance of early diagnosis in al amyloidosis to improve outcomes for patients
-
1:53
novel laboratory-based therapeutic approach in al amyloidosis: investigating flc secretion
-
16:56
lec 6: the biology of cancer (monoclonal growth)